Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about dividend policies following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 22, 2025, to request to lead the case [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health and has historically provided a healthy dividend to its shareholders [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, which was stated as its "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant dividend cut [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

Core Viewpoint - Organon & Co. is facing a securities class action lawsuit for failing to disclose material information during the class period, which has led to significant financial repercussions for the company and its investors [3][4]. Group 1: Lawsuit Details - Investors have until July 22, 2025, to file lead plaintiff applications in the lawsuit against Organon & Co. for securities purchased between October 31, 2024, and April 30, 2025 [1]. - The lawsuit is pending in the United States District Court for the District of New Jersey, under the case name Hauser V. Organon & Co., et al., No. 25-cv-05322 [5]. Group 2: Financial Impact - On March 10, 2025, Organon announced a drastic reduction in its dividend payout from $0.28 to $0.02, which contradicted previous assurances to investors regarding the importance of maintaining the dividend [4]. - Following the announcement of the dividend cut, Organon's share price plummeted over 27%, dropping from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025 [4]. Group 3: ClaimsFiler Information - ClaimsFiler is a free shareholder information service that assists investors in recovering funds from securities class action settlements [6]. - The service allows investors to register for free, upload portfolio data, and submit inquiries for case evaluations [6].

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly providing misleading statements regarding its capital allocation and dividend strategy, particularly following its acquisition of Dermavant [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Organon securities between October 31, 2024, and April 30, 2025 [1]. - Investors have until July 22, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations - Defendants allegedly made overwhelmingly positive statements while concealing material adverse facts about Organon's priorities, especially regarding capital allocation and debt reduction [3]. - The lawsuit highlights a significant reduction in the regular quarterly dividend by 70% due to the prioritization of debt reduction following the acquisition of Dermavant [3]. Group 3: Stock Price Impact - Following the news of the lawsuit, Organon's stock price dropped from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [4].

Group 1 - The class action was filed on behalf of investors who purchased Organon & Co. securities between October 31, 2024, and April 30, 2025 [1] - Organon is a global healthcare company focused on improving women's health throughout their lives [1] - The allegations include misleading statements regarding Organon's capital allocation strategy, particularly its prioritization of regular quarterly dividends [2] Group 2 - The complaint claims that while promoting a strong capital allocation strategy, Organon concealed the high priority of its debt reduction strategy following the acquisition of Dermavant, leading to a 70% decrease in the regular quarterly dividend [3] - The truth was revealed on May 1, 2025, when Organon announced a significant reduction in its dividend payout from $0.28 to $0.02, resulting in a stock price decline of over 27% [4] Group 3 - Shareholders interested in participating in the class action or serving as lead plaintiff are encouraged to contact the firm [5] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [6]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Organon & Co. securities for the period between October 31, 2024, and April 30, 2025, alleging misleading statements regarding the company's capital allocation and dividend strategy [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Organon provided positive statements to investors while concealing material adverse facts, particularly regarding its debt reduction strategy after acquiring Dermavant, which led to a 70% decrease in the regular quarterly dividend [5]. - Investors who purchased Organon securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must file a motion with the court by July 22, 2025, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for allegedly misrepresenting its capital allocation priorities and significantly reducing its quarterly dividend [1][7]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of New Jersey [1]. - Investors who acquired Organon shares during the class period (October 31, 2024 – April 30, 2025) are encouraged to contact the law firm before the lead plaintiff motion deadline on July 22, 2025 [1][3][7]. Group 2: Allegations Against Organon - Organon is accused of concealing material information regarding its capital allocation priorities, particularly in relation to its quarterly dividend [7]. - The company publicly emphasized dividends as a top priority while internally shifting focus towards debt reduction [7]. - Following the acquisition of Dermavant Sciences Ltd., Organon drastically reduced its quarterly dividend by over 90% [7]. Group 3: Law Firm Background - Wolf Haldenstein Adler Freeman & Herz LLP has over 125 years of legal expertise in securities litigation and aims to protect the rights of investors [4].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for misleading investors regarding its dividend policy following a significant acquisition [1][3]. Company Overview - Organon & Co. is a healthcare company based in Jersey City, NJ, focusing on women's health [2]. - In October 2024, Organon acquired Dermavant, a biopharmaceutical company, for $1.2 billion [2]. Financial Developments - Following the Dermavant acquisition, Organon increased its debt but assured investors that maintaining its dividend was a top priority [3]. - On May 1, 2025, Organon announced a drastic reduction in its dividend payout from $0.28 per share to $0.02 per share, indicating a shift in capital allocation priorities towards deleveraging [3]. - This announcement led to a significant decline in Organon's stock price, dropping approximately 27% from $12.93 to $9.45 per share [3].

Core Viewpoint - A class action securities lawsuit has been filed against Organon & Co. due to alleged securities fraud that negatively impacted investors between October 31, 2024, and April 30, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Organon's management made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding a significant debt reduction strategy following the acquisition of Dermavant [2] - As a result of these actions, Organon reduced its regular quarterly dividend by 70%, leading to a dramatic decline in stock price from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a drop of over 27% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders over the past 20 years and is recognized as one of the top securities litigation firms in the United States [4]

Group 1 - A class action lawsuit has been filed on behalf of purchasers of Organon & Co. securities between October 31, 2024, and April 30, 2025 [1] - Investors who purchased Organon securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - The lawsuit alleges that Organon's management provided misleading statements regarding the company's priorities, particularly concerning capital allocation and a significant reduction in quarterly dividends [5] Group 2 - The lawsuit claims that Organon concealed the importance of its debt reduction strategy following the acquisition of Dermavant, which led to a 70% decrease in the regular quarterly dividend [5] - Investors are encouraged to join the class action by contacting the Rosen Law Firm for more information [3][6] - The Rosen Law Firm has a strong track record in securities class actions, having recovered hundreds of millions of dollars for investors and being recognized for its success in this area [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to allegations of misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Organon & Co. provided overly positive statements to investors while concealing adverse facts about its priorities, particularly regarding capital allocation and a significant debt reduction strategy following the acquisition of Dermavant [3]. - The company’s regular quarterly dividend was reduced by 70%, which was not disclosed to investors prior to the announcement [3]. Stock Price Impact - Following the announcement of the dividend cut, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [3]. Class Action Details - The class period for the lawsuit is defined as October 31, 2024, to April 30, 2025, and shareholders are encouraged to register for participation in the class action [3][4]. - The deadline for shareholders to seek lead plaintiff status is July 22, 2025, and there is no cost or obligation to participate in the case [4]. Firm's Commitment - The Gross Law Firm aims to protect the rights of investors affected by deceit and fraud, ensuring companies adhere to responsible business practices [5].